ologen™ CM Patch Grafts Improve Ahmed Valve Treatment Success Rates by 127%

ologen™ CM Patch Grafts Improve Ahmed Valve Treatment Success Rates by 127%


According to a new 6-month Korean study published in the journal Investigative Ophthalmology & Visual Science, success rates of Ahmed Glaucoma Valve (AGV) surgeries soar and post-operative anti-glaucoma medication needs drop when said surgeries are performed in combination with biodegradable collagen patch grafts (commercially available as ologen™ CM).

Consisted of more than 90% atelocollagen, ologen™ CM is biodegradable and commercially available in dry form. It serves as a three-dimensional micro-scaffold that not only buffers the ocular aqueous flow but also encourages conjunctival fibroblasts to grow into its structure for healthy tissue formation.

Of the 43 AGV implantations performed, 22 were aided with patch grafts composed of biodegradable collagen. Those aided with the patch grafts see significantly healthier blebs, higher 6-monthtreatment success rate as well as lower dependence on anti-glaucoma medications for at least 6 months post-operation. These results can mean significantly improved life quality for many glaucoma patients undergoing AGV treatmentsand less drain on precious medical resource.

Aeon Astron Europe, the manufacturer of ologen™ CM is excited to learn of the new publication and believes it will help ologen™ CM in gaining approval for thepatch graft indication. The company expects the results of this study and others to be the incubator for more research interest to grow as well as more indication approvals to come.

Citation: Rho, S., Sung, Y., Ma, K., Rho, S., & Kim, C. (2015). Bleb Analysis and Short-Term Results of Biodegradable Collagen Matrix–Augmented Ahmed Glaucoma Valve Implantation: 6-Month Follow-up. Investigative Opthalmology & Visual Science Invest. Ophthalmol. Vis. Sci., 56(10), 5896-5896.

Funding: The authors reported no conflict of interest in the completion of this study